产品说明书
Monomethyl auristatin E
 |
同义名 : | MMAE;Vedotin;Brentuximab vedotin;SGD-1010 |
| CAS号 : | 474645-27-7 | |
| 货号 : | A172961 | |
| 分子式 : | C39H67N5O7 | |
| 纯度 : | 99%+ | |
| 分子量 : | 717.979 | |
| MDL号 : | MFCD22124498 | |
| 存储条件： |
粉末 Keep in dark place,Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(69.64 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO 无水乙醇: 45 mg/mL(62.68 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Monomethyl auristatin E (MMAE) produced under Good Manufacturing Practice (GMP) guidelines is a version of MMAE that inhibits tubulin polymerization[1]. | ||
| 作用机制 | MMAE binds to tubulin and interferes with microtubule formation.[4] | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02227199 | Recurrent Adult Hodgkin Lympho... 展开 >>ma Refractory Hodgkin Lymphoma TNFRSF8 Positive 收起 << | Phase 1 Phase 2 | Recruiting | - | United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Ajay K. Gopal 206-606-2037 agopal@u.washington.edu Principal Investigator: Ajay K. Gopal 收起 << |
| NCT00866047 | - | Completed | - | - | |
| NCT02001623 | Ovary Cancer ... 展开 >>Cervix Cancer Endometrium Cancer Bladder Cancer Prostate Cancer (CRPC) Esophagus Cancer Lung Cancer(NSCLC) Squamous Cell Carcinoma of the Head and Neck (SCCHN) 收起 << | Phase 1 Phase 2 | Active, not recruiting | December 2018 | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.39mL 0.28mL 0.14mL |
6.96mL 1.39mL 0.70mL |
13.93mL 2.79mL 1.39mL |
| 参考文献 |
|---|